Your browser doesn't support javascript.
Corticosteroids for COVID-19 symptoms and quality of life at 1 year from admission.
Catalán, Ignacio Pérez; Martí, Celia Roig; Sota, Daniela Palomo de la; Álvarez, Alejandro Cardenal; Gimeno, Maria José Esteve; Juana, Sergio Fabra; Rodríguez, Germán Herrero; Bajo, Elena Domínguez; Gaya, Nuria Tornador; Blasco, Jorge Usó; Rincón, Jose Manuel Ramos.
  • Catalán IP; Internal Medicine Service, University General Hospital of Castellon, Castellon, Spain.
  • Martí CR; Internal Medicine Service, University General Hospital of Castellon, Castellon, Spain.
  • Sota DP; Internal Medicine Service, University General Hospital of Castellon, Castellon, Spain.
  • Álvarez AC; Internal Medicine Service, University General Hospital of Castellon, Castellon, Spain.
  • Gimeno MJE; Internal Medicine Service, University General Hospital of Castellon, Castellon, Spain.
  • Juana SF; Internal Medicine Service, University General Hospital of Castellon, Castellon, Spain.
  • Rodríguez GH; Internal Medicine Service, University General Hospital of Castellon, Castellon, Spain.
  • Bajo ED; Internal Medicine Service, University General Hospital of Castellon, Castellon, Spain.
  • Gaya NT; Internal Medicine Service, University General Hospital of Castellon, Castellon, Spain.
  • Blasco JU; Internal Medicine Service, University General Hospital of Castellon, Castellon, Spain.
  • Rincón JMR; Internal Medicine Service, University General Hospital of Alicante, Alicante, Spain.
J Med Virol ; 94(1): 205-210, 2022 01.
Article in English | MEDLINE | ID: covidwho-1544337
ABSTRACT
The long-term evolution of COVID-19 is unknown, making it necessary to study the persistence of symptoms over time and their impact on quality of life in people who have had the disease. We analyzed these aspects 1 year after admission for COVID-19 and explored the influence of treatment with systemic corticosteroids during the acute phase of the illness. This observational cohort study took place in a tertiary hospital in March and April 2021 and included people admitted due to infection with SARS-CoV-2 in March, April, or May 2020. We excluded patients who had died, were unreachable or had substantial cognitive impairment. A telephone survey was undertaken to assess the presence of symptoms related to COVID-19 and to administer the SF-36 quality of life questionnaire. Other variables collected were demographic and clinical data along with the treatment received and the evolution over time. We analyzed 76 patients, including 44 who did not receive corticosteroids and 32 who did. Most symptoms were less frequent in the group that received corticosteroids, with statistically significant differences for headache, dysphagia, chest pain, and depression. These patients also showed significantly better outcomes in the SF-36 domains for "bodily pain" and "mental health." Corticosteroids administered in the acute phase of COVID-19 could attenuate the presence of long-term symptoms and improve patients' quality of life.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Quality of Life / Adrenal Cortex Hormones / COVID-19 Drug Treatment Type of study: Cohort study / Observational study / Prognostic study Topics: Long Covid Limits: Aged / Female / Humans / Male / Middle aged Language: English Journal: J Med Virol Year: 2022 Document Type: Article Affiliation country: Jmv.27296

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Quality of Life / Adrenal Cortex Hormones / COVID-19 Drug Treatment Type of study: Cohort study / Observational study / Prognostic study Topics: Long Covid Limits: Aged / Female / Humans / Male / Middle aged Language: English Journal: J Med Virol Year: 2022 Document Type: Article Affiliation country: Jmv.27296